911 related articles for article (PubMed ID: 30298064)
1. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
2. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
3. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
6. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.
Li H; Liu Y; Tian D; Tian L; Ju X; Qi L; Wang Y; Liang C
Eur J Med Chem; 2020 Apr; 192():112163. PubMed ID: 32109623
[TBL] [Abstract][Full Text] [Related]
7. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
9. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
[TBL] [Abstract][Full Text] [Related]
11. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol in sport: Ergogenic or else?
Gamelin FX; Cuvelier G; Mendes A; Aucouturier J; Berthoin S; Di Marzo V; Heyman E
Pharmacol Res; 2020 Jun; 156():104764. PubMed ID: 32205233
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW
Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
17. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
Sarris J; Sinclair J; Karamacoska D; Davidson M; Firth J
BMC Psychiatry; 2020 Jan; 20(1):24. PubMed ID: 31948424
[TBL] [Abstract][Full Text] [Related]
18. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
[TBL] [Abstract][Full Text] [Related]
19. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
